AstraZeneca's Newly Acquired COVID Antibody Could Protect Against Known Variants, Executive Says - AstraZeneca (NASDAQ:AZN), AstraZeneca (OTC:AZNCF)

AstraZeneca plc's AZN vaccine head highlighted the confidence that the company's new COVID-19 antibody treatment could protect immunocompromised patients against all known virus variants.
Laboratory studies show that the antibody, dubbed AZD3152, neutralizes all known variants of COVID-19.
AstraZeneca has support from regulators to make the treatment available by the end of this year, Reuters reported citing Iskra Reic's interview.
Depending on additional encouraging data and regulatory approval, AstraZeneca plans to make the antibody available by the end of 2023.
Also Read: AstraZeneca Forecasts Growth In 2023 Earnings, Revenue Despite Fall In COVID-19 Products, Plans To Deliver 15 New Medicines This Decade.
In January, the FDA withdrew its emergency use authorization for AstraZeneca's original COVID-19 antibody cocktail Evusheld.
Data showed Evusheld was not active against certain SARS-CoV-2 variants that accounted for over 90% of the infections in the U.S., rendering it obsolete.
AstraZeneca's AZD3152, its new COVID-19 antibody, was acquired through a $157 million deal in May last year from British biotech start-up RQ Biotechnology Ltd.
In January, AZD3152 entered clinical trials. The start of AstraZeneca's SUPERNOVA Phase I/III trial will investigate AZD5156 (a combination of AZD3152 and cilgavimab) in pre-exposure prevention of COVID-19.
Price Action: AZN shares are up 1.38% at $74.65 on the last check Tuesday.
Photo by Paul McManus from Pixaba

Why AstraZeneca Shares Are Trading Higher Today?